Basilea Pharmaceutica (XSWX:BSLN) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
64 GF Score
Price CHF62.50
GF Value CHF58.06
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Short-term investments?

Short-term investments only applies to insurance companies.

XSWX:BSLN
64GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be overvalued. The current stock price of CHF62.50 is trading 7.6% above its estimated GF Value™ of CHF58.06. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Short-term investments:
  • GF Value™: CHF58.06 vs. price of CHF62.50 (7.6% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
64GF Score

Get the complete analysis for XSWX:BSLN

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF62.50
Price
CHF58.06
GF Value